Fortitude CEO Thomas J. Parilla announced that the company has entered into a joint venture agreement to obtain the USA production/sales/distribution and licensing rights for a revolutionary medical marijuana product MariMist for the use in the care of cancer patients with MariMedical Pharmaceuticals. Additional clinical applications include the treatment of nausea, anxiety and pain relief. The terms of the JV agreement are extremely beneficial to Fortitude and its shareholders.

As all revenues pass through the company, 92% will remain with Fortitude with a small royalty payment of 8% based on the wholesale price being paid to MariMedical. The agreement is for three years with an automatic extension for seven years triggered when certain modest sales goals are achieved. Fortitude also has a one year option to acquire the international licensing rights for Mari-Mist, along with the right of first refusal for any future products solely developed by MMP.